American Journal of Kidney Diseases
Volume 46, Issue 2 , Pages 270-277 , August 2005

Renal Response After High-Dose Melphalan and Stem Cell Transplantation Is a Favorable Marker in Patients With Primary Systemic Amyloidosis

Received 18 January 2005 ,Accepted 2 May 2005.

References 

  1. Glenner GG , Terry W , Harada M , Isersky C , Page D . Amyloid fibril proteins (Proof of homology with immunoglobulin light chains by sequence analyses) . Science . 1971;172:1150–1151
  2. Terry WD , Page DL , Kimura S , Isobe T , Osserman EF , Glenner GG . Structural identity of Bence-Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis . J Clin Invest . 1973;52:1276–1281
  3. Gertz MA , Kyle RA . Amyloidosis with IgM monoclonal gammopathies . Semin Oncol . 2003;30:325–328
  4. Gertz MA , Kyle RA , Noel P . Primary systemic amyloidosis (A rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom’s macroglobulinemia) . J Clin Oncol . 1993;11:914–920
  5. Kyle RA , Gertz MA . Primary systemic amyloidosis (Clinical and laboratory features in 474 cases) . Semin Hematol . 1995;32:45–59
  6. Kyle RA , Greipp PR , O’Fallon WM . Primary systemic amyloidosis (Multivariate analysis for prognostic factors in 168 cases) . Blood . 1986;68:220–224
  7. Gertz MA , Kyle RA , O’Fallon WM . Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients . Arch Intern Med . 1992;152:2245–2250
  8. Gertz MA , Lacy MQ , Lust JA , Greipp PR , Witzig TE , Kyle RA . Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis . Med Oncol . 1999;16:104–109
  9. Gertz MA , Lacy MQ , Lust JA , Greipp PR , Witzig TE , Kyle RA . Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis . J Clin Oncol . 1999;17:262–267
  10. Kyle RA , Gertz MA , Greipp PR , et al.   A trial of three regimens for primary amyloidosis (Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine) . N Engl J Med . 1997;336:1202–1207
  11. Skinner M , Anderson J , Simms R , et al.   Treatment of 100 patients with primary amyloidosis (A randomized trial of melphalan, prednisone, and colchicine versus colchicine only) . Am J Med . 1996;100:290–298
  12. Kyle RA , Greipp PR , Garton JP , Gertz MA . Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine . Am J Med . 1985;79:708–716
  13. Majolino I , Marceno R , Pecoraro G , et al.   High-dose therapy and autologous transplantation in amyloidosis-AL . Haematologica . 1993;78:68–71
  14. Skinner M , Sanchorawala V , Seldin DC , et al.   High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis (An 8-year study) . Ann Intern Med . 2004;140:85–93
  15. Dember LM , Sanchorawala V , Seldin DC , et al.   Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease . Ann Intern Med . 2001;134:746–753
  16. Wilson DM , Bergert JH , Larson TS , Liedtke RR . GFR determined by nonradiolabeled iothalamate using capillary electrophoresis . Am J Kidney Dis . 1997;30:646–652
  17. Gertz MA , Lacy MQ , Dispenzieri A , et al.   Stem cell transplantation for the management of primary systemic amyloidosis . Am J Med . 2002;113:549–555
  18. Lachmann HJ , Gallimore R , Gillmore JD , et al.   Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy . Br J Haematol . 2003;122:78–84
  19. Dispenzieri A , Lacy MQ , Kyle RA , et al.   Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival . J Clin Oncol . 2001;19:3350–3356
  20. Dispenzieri A , Kyle RA , Lacy MQ , et al.   Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation (A case-control study) . Blood . 2004;103:3960–3963
  21. Katzmann JA , Clark RJ , Abraham RS , et al.   Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains (Relative sensitivity for detection of monoclonal light chains) . Clin Chem . 2002;48:1437–1444
  22. Mollee PN , Wechalekar AD , Pereira DL , et al.   Autologous stem cell transplantation in primary systemic amyloidosis (The impact of selection criteria on outcome) . Bone Marrow Transplant . 2004;33:271–277
  23. Jones NF , Hilton PJ , Tighe JR , Hobbs JR . Treatment of “primary” renal amyloidosis with melphalan . Lancet . 1972;2:616–619
  24. Schwartz RS , Cohen JR , Schrier SL . Therapy of primary amyloidosis with melphalan and prednisone . Arch Intern Med . 1979;139:1144–1147
  25. Kyle RA , Wagoner RD , Holley KE . Primary systemic amyloidosis (Resolution of the nephrotic syndrome with melphalan and prednisone) . Arch Intern Med . 1982;142:1445–1447
  26. Kyle RA , Greipp PR . Primary systemic amyloidosis (Comparison of melphalan and prednisone versus placebo) . Blood . 1978;52:818–827
  27. Dhodapkar MV , Jagannath S , Vesole D , et al.   Treatment of AL-amyloidosis with dexamethasone plus alpha interferon . Leuk Lymphoma . 1997;27:351–356
  28. Fujimoto S , Hara S , Sato Y , Yamada K , Hisanaga S , Eto T . Nephrotic syndrome caused by membranous nephropathy (Response to a short course of cyclophosphamide alternating with prednisolone) . Intern Med . 2004;43:30–34
  29. Fioretto P , Steffes MW , Sutherland DE , Goetz FC , Mauer M . Reversal of lesions of diabetic nephropathy after pancreas transplantation . N Engl J Med . 1998;339:69–75
  30. Jones BA , Shapiro HS , Rosenberg BF , Bernstein J . Minimal renal amyloidosis with nephrotic syndrome . Arch Pathol Lab Med . 1986;110:889–892
  31. Fujigaki Y , Takahashi S , Yonemura K , et al.   Longterm complete remission of AL-amyloid-related nephrotic syndrome . Clin Exp Nephrol . 2003;7:250–253
  32. Fadia A , Casserly LF , Sanchorawala V , et al.   Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis . Kidney Int . 2003;63:1868–1873
  33. Hachulla E , Maulin L , Deveaux M , et al.   Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy (From diagnosis to prognosis) . Am J Med . 1996;101:77–87
  34. Hawkins PN . Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis . Curr Opin Nephrol Hypertens . 2002;11:649–655
  35. Saile R , Deveaux M , Hachulla E , Descamps J , Duquesnoy B , Marchandise X . Iodine-123-labelled serum amyloid P component scintigraphy in amyloidosis . Eur J Nucl Med . 1993;20:130–137

 Originally published online as doi:10.1053/j.ajkd.2005.05.010 on June 21, 2005.

PII: S0272-6386(05)00623-2

doi: 10.1053/j.ajkd.2005.05.010

American Journal of Kidney Diseases
Volume 46, Issue 2 , Pages 270-277 , August 2005

Article Tools

* Image Usage & Resolution